Short-term Clinical Performance of Multifocal Soft Contact Lens

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05273606
Collaborator
(none)
40
1
1
3.1
13.1

Study Details

Study Description

Brief Summary

The study is aimed to observe the short-term clinical performance of MiSight™ multifocal soft contact lens compared with Proclear™ 1day, including objective examination, subjective acceptability of wearers, and doctors' evaluation of the clinical manifestations of lenses.

Condition or Disease Intervention/Treatment Phase
  • Device: MiSight mutifocal soft contact lens
  • Device: Proclear 1 Day soft contact lens
N/A

Detailed Description

Compared with Proclear™ 1day, observe the short-term clinical performance of MiSight™ multifocal soft contact lens including objective examination, subjective acceptability of wearers, and doctors' evaluation of the clinical manifestations of lenses in 1 month.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Clinical Study of Short-term Clinical Performance of Multifocal Soft Contact Lens
Anticipated Study Start Date :
Apr 30, 2022
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Group

Device: MiSight mutifocal soft contact lens
Subjects will wear MiSight™ multifocal soft contact lenses for 1 month.

Device: Proclear 1 Day soft contact lens
Proclear™ 1 Day soft contact lens will be worn for baseline evaluation.

Outcome Measures

Primary Outcome Measures

  1. Change in the contrast sensitivity visual function (CSF) relative to baseline at 1 month [Proclear baseline;VMisight baseline; 1 week; 1month]

Secondary Outcome Measures

  1. Patients' subjective acceptability to multifocal soft contact lens [Proclear baseline; Misight baseline; 1 week; 1month]

    The patients will be asked to complete questionnaires at each visit regarding vision, lens comfort, the difficulty of lens insert and removal, etc. of the multifocal contact lens.

  2. Doctors' clinical evaluation to multifocal soft contact lens [Proclear baseline; Misight baseline; 1 week; 1month]

    The doctors will be asked to complete questionnaires regarding the difficulty of fitting procedure and general impression of the multifocal contact lens.

  3. Change in the contact lens corrected visual acuity relative to baseline [Proclear baseline;Misight baseline;1 week;1month]

    Patients will wear contact lens when they are tested

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • • Prior to being considered eligible to participate in this study, each subject MUST:
  1. Be between 8 and 12 years of age inclusive at the baseline examination.

  2. Have:

  3. read the Informed Assent,

  4. been given an explanation of the Informed Assent,

  5. indicated an understanding of the Informed Assent and

  6. signed the Informed Assent Form.

  7. Have their parent or legal guardian:

  8. read the Informed Consent,

  9. been given an explanation of the Informed Consent,

  10. indicated an understanding of the Informed Consent and

  11. signed the Informed Consent Form.

  12. Along with their parent or guardian, be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol.

  13. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study.

  14. Agree to wear the assigned contact lenses for the duration of the 1-month study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.)

  15. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline:

  16. Spherical refractive error: between -0.75 and -4.00 D inclusive,

  17. Astigmatism: ≤-0.75 D,

  18. Anisometropia: ≤1.50D,

  19. Best-corrected visual acuity :≥0.8.

Exclusion Criteria:
  • • Subjects may not be considered eligible if ANY of the following apply:
  1. Subject has regular use of ocular medications.

  2. Any systemic disease which is not suggested to wear contact lens or current use of systemic medications which may significantly affect contact lens wear, visual function, or refractive state.

  3. A history of ocular trauma or ocular surgery in the last 8 weeks.

  4. Subject has worn rigid gas permeable contact lenses in the last 6 weeks, including orthokeratology lenses.

  5. Abnormal secretion or excretion of tear fluid, infection of the tear ducts, or other recurrent ocular infections.

  6. A known allergy to fluorescein, benoxinate, proparacaine, or tropicamide.

  7. Keratoconus or an irregular cornea.

  8. Subjects who have been in a special environment such as dryness, serious dust, or volatile chemicals for a long time affect the wear of contact lenses.

  9. Strabismus, amblyopia patients, only one eye meets the admission conditions.

  10. Subject is currently an active participant in another clinical study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong China 510060

Sponsors and Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xiao Yang, Principal Investigator, Clinical Professor, Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT05273606
Other Study ID Numbers:
  • 2021KYPJ202
First Posted:
Mar 10, 2022
Last Update Posted:
Apr 12, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2022